Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,088 across all filing types
Latest filing 2023-04-14 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
独立董事关于相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on various matters related to the company's 2022 annual report and related issues. It discusses topics such as related party transactions, external guarantees, profit distribution, internal control evaluation, audit firm reappointment, remuneration, cash management, accounting error corrections, and independent director nominations. The document is a formal opinion letter from independent directors rather than the annual report itself. It references the 2022 annual report but does not contain the full financial statements or comprehensive financial data. The length is relatively short (2126 characters), and the content is focused on independent directors' opinions and confirmations rather than the full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a formal regulatory disclosure related to the annual report but not the report itself.
2023-04-14 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 10th meeting of the 3rd Board of Directors of Xiamen Aide Biological Pharmaceutical Technology Co., Ltd. It includes approvals of the 2022 annual general manager work report, board work report, financial statements, annual report, profit distribution plan, internal control self-evaluation report, audit firm reappointment, credit line application, cash management, accounting error correction, independent director election and remuneration adjustment, and the scheduling of the 2022 annual shareholders meeting. The document references the 2022 annual report and other detailed reports published on the China Securities Regulatory Commission designated information disclosure website but does not contain the full annual report itself. The document is a formal board meeting resolution announcement, which is typically classified as Board/Management Information (MANG). The document length is about 4700 characters, which is consistent with a detailed board meeting announcement rather than a full annual report or other report type. Therefore, the correct classification is MANG with high confidence.
2023-04-14 Chinese
2022年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled '2022 年度监事会工作报告' which translates to '2022 Supervisory Board Work Report'. It details the supervisory board's activities, meetings, and oversight of company operations, financials, internal controls, related party transactions, and compliance during the 2022 fiscal year. It is a report from the supervisory board rather than a full annual report or audit report. The document length is 1959 characters, which is relatively short but contains substantive content about supervisory board work and oversight. This type of document aligns with a Management Report or Supervisory Board Report rather than an Annual Report (10-K) or Audit Report (AR). Given the content and nature, the best fitting category is Management Reports (MDA).
2023-04-14 Chinese
独立董事候选人声明
Regulatory Filings Classification · 95% confidence The document is a formal declaration by an independent director candidate of a company, confirming compliance with various legal and regulatory requirements for serving as an independent director. It contains no financial data, no report or presentation, and no announcement of voting results or management changes. It is a regulatory compliance statement related to board/management qualifications but does not announce a change or provide detailed management information. Given the nature of the document as a formal declaration related to board membership qualifications, it best fits under Regulatory Filings (RNS) as a compliance document that does not fit other categories.
2023-04-14 Chinese
2022年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告及财务报表" which translates to "Audit Report and Financial Statements" for the fiscal year 2022. It contains detailed audit opinions, key audit matters, management responsibilities, and extensive financial statements including consolidated and parent company balance sheets, income statements, cash flow statements, and notes. The presence of a formal audit opinion by a registered accounting firm and comprehensive financial data confirms this is a full audit report with financial statements, not just an announcement or certification. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. Therefore, the document fits the category of an Audit Report / Information (AR).
2023-04-14 Chinese
关于使用部分闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Xiamen Aide Bio-Pharmaceutical Technology Co., Ltd. regarding the use of part of its idle own funds for cash management. It details the investment purpose, types, amount, decision validity period, implementation method, funding source, approval procedures, risk control measures, and opinions from independent directors and the supervisory board. The document is a formal disclosure about a financing or capital management activity, specifically the use of idle funds for cash management and investment in low-risk products. It is not a financial report, earnings release, or management discussion. It is also not a regulatory certification or a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities and capital management plans. The document length is 2087 characters, which is relatively short but contains substantive information about capital use, not just a brief notice or report publication announcement. Therefore, the classification is CAP with high confidence.
2023-04-14 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.